Positive News SentimentPositive NewsNASDAQ:EYPT EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis $23.11 -0.45 (-1.91%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$22.12▼$23.8250-Day Range$5.71▼$24.1352-Week Range$2.21▼$24.62Volume926,194 shsAverage Volume3.08 million shsMarket Capitalization$1.09 billionP/E RatioN/ADividend YieldN/APrice Target$32.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media EyePoint Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside40.6% Upside$32.50 Price TargetShort InterestHealthy10.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.61Based on 4 Articles This WeekInsider TradingAcquiring Shares$51.87 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.05) to ($1.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.68 out of 5 starsMedical Sector70th out of 950 stocksAnalytical Instruments Industry4th out of 26 stocks 3.5 Analyst's Opinion Consensus RatingEyePoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.50, EyePoint Pharmaceuticals has a forecasted upside of 40.6% from its current price of $23.11.Amount of Analyst CoverageEyePoint Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted10.09% of the outstanding shares of EyePoint Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in EyePoint Pharmaceuticals has recently decreased by 32.24%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEyePoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyePoint Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EYPT. Previous Next 4.2 News and Social Media Coverage News SentimentEyePoint Pharmaceuticals has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for EyePoint Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest24 people have searched for EYPT on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.MarketBeat Follows8 people have added EyePoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, EyePoint Pharmaceuticals insiders have bought 776.15% more of their company's stock than they have sold. Specifically, they have bought $51,873,819.00 in company stock and sold $5,920,675.00 in company stock.Percentage Held by Insiders13.05% of the stock of EyePoint Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.41% of the stock of EyePoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for EyePoint Pharmaceuticals are expected to grow in the coming year, from ($2.05) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of EyePoint Pharmaceuticals is -8.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of EyePoint Pharmaceuticals is -8.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyePoint Pharmaceuticals has a P/B Ratio of 8.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About EyePoint Pharmaceuticals Stock (NASDAQ:EYPT)EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, which is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Read More EYPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EYPT Stock News HeadlinesDecember 20, 2023 | finance.yahoo.comEyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2023 | finance.yahoo.comWhat EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 194% Share Price Gain Is Not Telling YouDecember 31, 2023 | MarketBeat Internal (Ad)MarketBeat All Access New Year's Sale - Just $1.00Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.December 17, 2023 | msn.comEyePoint Pharmaceuticals (EYPT) Price Target Increased by 37.87% to 42.50December 13, 2023 | finance.yahoo.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Trimmed Their Revenue Forecasts By 11%December 11, 2023 | msn.comCapital One Initiates Coverage of EyePoint Pharmaceuticals (EYPT) with Overweight RecommendationDecember 11, 2023 | finance.yahoo.comEyePoint Pharmaceuticals (EYPT) is a Great Momentum Stock: Should You Buy?December 11, 2023 | finance.yahoo.comInstitutional investors have a lot riding on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) with 43% ownershipDecember 31, 2023 | MarketBeat Internal (Ad)MarketBeat All Access New Year's Sale - Just $1.00Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.December 8, 2023 | finance.yahoo.comEyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional SharesDecember 8, 2023 | finance.yahoo.comWhat Makes EyePoint Pharmaceuticals (EYPT) a Good Fit for 'Trend Investing'December 8, 2023 | finance.yahoo.comWall Street Analysts Believe EyePoint Pharmaceuticals (EYPT) Could Rally 77.05%: Here's is How to TradeDecember 8, 2023 | benzinga.comThis Tech Stock Is 'Too Expensive,' Cramer Says: 'Wait For A Pullback'December 7, 2023 | msn.comInsider Trading: EyePoint’s (NASDAQ:EYPT) Insider Makes an Enormous PurchaseDecember 7, 2023 | finance.yahoo.comInsider Sell Alert: Chief Corp Dev. & Strat.December 7, 2023 | finance.yahoo.comInsider Sell Alert: Chief Corp Dev. & Strat. ...December 6, 2023 | benzinga.comEyePoint Pharmaceuticals Stock (NASDAQ:EYPT) Dividends: History, Yield and DatesDecember 6, 2023 | markets.businessinsider.comBuy Rating Affirmed for EyePoint Pharmaceuticals Following EYP-1901’s Promising Trial OutcomesDecember 6, 2023 | msn.comEyePoint Pharmaceuticals prices upsized $200 million stock offeringDecember 5, 2023 | finance.yahoo.comEyePoint Pharmaceuticals Announces Pricing of Upsized Public OfferingDecember 5, 2023 | msn.comEyePoint data suggest time-released drug may help patients with macular degenerationDecember 5, 2023 | finance.yahoo.comEyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease DataDecember 5, 2023 | seekingalpha.comEyePoint Pharmaceuticals Soaring On Wet AMD Study Results: Durasert Looks Real DealDecember 5, 2023 | msn.comCrude Oil Falls Over 1%; EyePoint Pharmaceuticals Shares Spike HigherDecember 4, 2023 | investing.comAfter-hours movers: GitLab surges on earnings, EyePoint adds to intra-day gainsDecember 4, 2023 | msn.comEyePoint Pharmaceuticals’ stock soars 200% after company announces positive data for macular degeneration treatmentDecember 4, 2023 | bizjournals.comWatertown biotech shares surge nearly 200% on new drug dataSee More Headlines Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today12/31/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYPT CUSIPN/A CIK1314102 Webeyepointpharma.com Phone(617) 926-5000Fax617-926-5050Employees144Year Founded1987Price Target and Rating Average Stock Price Target$32.50 High Stock Price Target$44.00 Low Stock Price Target$22.00 Potential Upside/Downside+40.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,250,000.00 Net Margins-235.51% Pretax Margin-235.51% Return on Equity-109.34% Return on Assets-47.39% Debt Debt-to-Equity RatioN/A Current Ratio2.35 Quick Ratio2.28 Sales & Book Value Annual Sales$41.40 million Price / Sales26.28 Cash FlowN/A Price / Cash FlowN/A Book Value$2.83 per share Price / Book8.17Miscellaneous Outstanding Shares47,070,000Free Float40,931,000Market Cap$1.09 billion OptionableOptionable Beta1.25 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Jay S. Duker M.D. (Age 64)President, CEO & Director Comp: $848.5kMr. Michael Pine (Age 47)Chief Business Officer Comp: $764.85kMr. George O. Elston (Age 58)Executive VP & CFO Comp: $743.86kMr. Michael J. MaciocioSenior Vice President of Manufacturing & OperationsMr. Said Saim Ph.D. (Age 65)Senior VP & CTO Mr. Ron I. Honig Esq.Chief Legal Officer & Company SecretaryMs. Jennifer LeonardChief People Officer & Senior VP of ITDr. Dario A. Paggiarino (Age 66)Senior VP & Chief Medical Officer Comp: $694.19kMr. David Scott Jones (Age 56)Senior VP & Chief Commercial Officer Comp: $672.08kMs. Isabelle LefebvreChief Regulatory OfficerMore ExecutivesKey CompetitorsQuanterixNASDAQ:QTRXCytek BiosciencesNASDAQ:CTKBNautilus BiotechnologyNASDAQ:NAUTFluidigmNASDAQ:FLDMHarvard BioscienceNASDAQ:HBIOView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 37,486 shares on 12/18/2023Ownership: 3.061%Dario A PaggiarinoSold 1,458 sharesTotal: $29,160.00 ($20.00/share)Cormorant Asset Management, LpBought 588,235 shares on 12/8/2023Total: $10.00 M ($17.00/share)Ye LiuSold 266,242 sharesTotal: $4.90 M ($18.41/share)Cormorant Asset Management, LpBought 1,919,057 shares on 12/4/2023Total: $41.87 M ($21.82/share)View All Insider TransactionsView All Institutional Transactions EYPT Stock Analysis - Frequently Asked Questions Should I buy or sell EyePoint Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EYPT shares. View EYPT analyst ratings or view top-rated stocks. What is EyePoint Pharmaceuticals' stock price target for 2024? 6 equities research analysts have issued 1 year price targets for EyePoint Pharmaceuticals' stock. Their EYPT share price targets range from $22.00 to $44.00. On average, they anticipate the company's stock price to reach $32.50 in the next twelve months. This suggests a possible upside of 40.6% from the stock's current price. View analysts price targets for EYPT or view top-rated stocks among Wall Street analysts. How have EYPT shares performed in 2023? EyePoint Pharmaceuticals' stock was trading at $3.50 at the start of the year. Since then, EYPT stock has increased by 560.3% and is now trading at $23.11. View the best growth stocks for 2023 here. When is EyePoint Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024. View our EYPT earnings forecast. How were EyePoint Pharmaceuticals' earnings last quarter? EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) announced its quarterly earnings data on Wednesday, November, 1st. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.29. The company had revenue of $15.20 million for the quarter, compared to analyst estimates of $3.90 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 109.34% and a negative net margin of 235.51%. When did EyePoint Pharmaceuticals' stock split? EyePoint Pharmaceuticals shares reverse split on the morning of Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of EyePoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX). How do I buy shares of EyePoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EYPT) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.